You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

  • Authors: Frederick R. Appelbaum, MD; Stephen J. Forman, MD; Gail J. Roboz, MD; David Steensma, MD; Willis Navarro, MD
  • CME Released: 5/21/2013; Reviewed and Renewed: 9/23/2014
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 9/23/2015, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, and other healthcare professionals who treat patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

The goal of this activity is to discuss the latest approaches to the treatment of older patients with MDS and AML.

Upon completion of this activity, participants will be able to:

  1. Identify disease- and patient-related factors that predict outcomes of hematopoietic cell transplantation (HCT), new drugs, or combination therapy in older patients with MDS and AML
  2. Explain recent clinical trial results that have influenced the selection of patients for treatment of MDS and AML
  3. Compare the risks and benefits of treatment options and how timing of therapy choices affects outcomes
  4. Describe appropriate candidates for a prospective study on outcomes of HCT in adults 65 years of age and older with MDS


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Frederick R. Appelbaum, MD

    Executive Director, Seattle Cancer Care Alliance; Director, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine, Seattle, Washington

    Disclosures

    Disclosure: Frederick R. Appelbam, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Celator Pharmaceuticals, Inc.; Pfizer Inc; Igenica, Inc.; Abbott Laboratories

    Dr Appelbaum does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Appelbaum does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Stephen J. Forman, MD

    Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation; Clinical Director, Cancer Immunotherapeutics & Tumor Immunology, City of Hope, Duarte, California

    Disclosures

    Disclosure: Stephen J. Forman, MD, has disclosed no relevant financial relationships.

    Dr Forman does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Forman does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Gail J. Roboz, MD

    Director, Leukemia Program; Associate Professor of Medicine, Weill Medical College, Cornell University, New York, New York

    Disclosures

    Disclosure: Gail J. Roboz, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Celgene Corporation

    Dr Roboz does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Roboz does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • David Steensma, MD

    Associate Professor of Medicine, Harvard Medical School; Adult Leukemia Program, Dana-Farber Cancer Institute; Hematological Oncology Service, Brigham & Women’s Hospital, Boston, Massachusetts

    Disclosures

    Disclosure: David Steensma, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Genoptix, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Amgen Inc.

    Dr Steensma does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Steensma does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States

  • Willis Navarro, MD

    Vice President, Transplant Medical Services, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

    Current position: Vice President of Clinical Research and Development at Atara Biotherapeutics and Associate Clinical Professor of Medicine at the University of California, San Francisco

    Disclosures

    Disclosure: Willis Navarro, MD, has disclosed no relevant financial relationships.

    Dr Navarro does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Navarro does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

  • Charlotte Warren

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

  • Ellyce Hayes

    Strategic Marketing Specialist, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

    Disclosures

    Disclosure: Ellyce Hayes has disclosed no relevant financial relationships.

  • Alissa Salvato

    Medical Education Outreach Specialist, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

    Disclosures

    Disclosure: Alissa Salvato has disclosed no relevant financial relationships.

  • Tim Walker

    Medical Writer, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota

    Disclosures

    Disclosure: Tim Walker has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients

Authors: Frederick R. Appelbaum, MD; Stephen J. Forman, MD; Gail J. Roboz, MD; David Steensma, MD; Willis Navarro, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 5/21/2013; Reviewed and Renewed: 9/23/2014

Valid for credit through: 9/23/2015, 11:59 PM EST

processing....

Editor's Note: Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients is adapted from the live presentation held before the December 2012 annual meeting of the American Society of Hematology (ASH). This activity is sponsored by the National Marrow Donor Program®/Be The Match® and is certified for CME by Medscape.

Contents of This CME Activity

All sections of this activity are required for credit.

Section 1. Applying Novel Diagnostics and Therapeutics for AML in the Older Patient
Dr Gail Roboz reviews existing and evolving approaches to the treatment of patients with AML.
Gail J. Roboz, MD
Section 2. Allogeneic HCT for the Older Patient With AML
Dr Frederick Appelbaum examines the indications for allogeneic transplant among patients 50 years of age and older.
Frederick R. Appelbaum, MD
Section 3. Drug Therapy for MDS: Targets and Biomarkers
Dr David Steensma discusses the rise of targeted therapies and other novel approaches for the treatment of MDS.
David Steensma, MD
Section 4. MDS and AlloHCT: Weighing Risks and Benefits, and the Need to Learn More
Dr Stephen Forman explores optimal timing and other important issues in the use of allogeneic HCT for patients with MDS.
Stephen J. Forman, MD
Section 5. Case Discussion
Drs Gail Roboz, Frederick Appelbaum, David Steensma, and Stephen Forman discuss 4 cases of older patients with AML and MDS.
Frederick R. Appelbaum, MD; Stephen J. Forman, MD; Gail J. Roboz, MD; David Steensma, MD
  • Print